Hyundai Pharmaceutical Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hyundai Pharmaceutical Company Limited with three other
companies in this sector in KOREA (SOUTH) :
Theragen Etex Co Limited
sales of 138.08 billion Korean Won [US$121.10 million]
of which 86%
was Pharmaceutical Business Segment),
Dae Han New Pharm Co., Ltd.
(134.10 billion Korean Won [US$117.60 million]
of which 81%
was Finished Goods), and
Reyon Pharmaceutical Co Ltd
(131.56 billion Korean Won [US$115.38 million]
of which 33%
was other finished goods).
During the year ended November of 2019, sales at
Hyundai Pharmaceutical Company Limited were 134.92 billion Korean Won (US$118.33 million).
a very small
increase of 0.7%
versus 2018, when the company's sales were 133.94 billion Korean Won .
This was the fifth consecutive year of sales increases at Hyundai Pharmaceutical Company Limited
(and since 2014, sales have increased a total of 25%).
Sales of Food saw an increase
that was more than double the company's growth rate: sales were up
12.2% in 2019, from
15.39 billion Korean Won to 17.26 billion Korean Won .
Not all segments of Hyundai Pharmaceutical Company Limited experienced an increase in sales in 2019:
sales of Pharmaceutical fell 7.6% to 109.53 billion Korean Won .